Financings in Brief: ThermoLase
This article was originally published in The Gray Sheet
ThermoLase: Agrees to acquire 10% stake in AntiCancer Inc. via a $4.4 mil. investment in the San Diego biotech firm. ThermoLase says a technology under development by AntiCancer "has potential to enhance the effectiveness of the Thira cream used in ThermoLase's SoftLight hair-removal process." AntiCancer technologies also show promise for use in "permanent hair coloring and for enhanced hair growth," ThermoLase says, noting that it has entered a separate agreement licensing the technology for "these and other potential hair-related products." The exclusive, worldwide licensing agreement calls for ThermoLase to pay $100,000 up front and up to $1.5 mil. in milestone payments, as well as royalty payments on "any products developed"...
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.